Atypical cutaneous melanocytic lesions, including those with Spitzoid features, can be difficult to categorize as benign or malignant. This can lead to suboptimal management, with potential adverse patient outcomes. Recent studies have enhanced knowledge of the molecular and genetic biology of these lesions and, combined with clinicopathological findings, is further defining their biological spectrum, classification, and behavior. Sentinel node biopsy provides important prognostic information in patients with cutaneous melanoma, but its role in the management of melanocytic lesions of uncertain malignant potential (MELTUMP) is controversial. This paper examines the role of molecular testing and sentinel node biopsy in MELTUMPs, particularly atypical Spitzoid tumors.
Jonathan J. Lee, Ricardo E. Vilain, Scott R. Granter, Nina R. Hu, Scott C. Bresler, Shuyun Xu, Alexander Frank, Martín C. Mihm, Robyn P.M. Saw, Christopher D.�M. Fletcher, Richard A Scolyer, Gëorge F. Murphy, Christine G. Lian
Raymond L. Barnhill, Lorenzo Cerroni, Martin Cook, David E. Elder, Helmut Kerl, Philip E. LeBoit, Stanley W. McCarthy, Martín C. Mihm, Wolter J. Mooi, Michael W. Piepkorn, Víctor G. Prieto, Richard A Scolyer
Pedram Gerami, Richard A Scolyer, Xiaowei Xu, David E. Elder, Ronnie M. Abraham, Douglas R. Fullen, Víctor G. Prieto, Philip E. LeBoit, Raymond L. Barnhill, Chelsea Cooper, Pedram Yazdan, Joan Guitart, Ping Liu, Ekaterina Pestova, Klaus J. Busam
Discussion(0)
No comments yet. Be the first to comment.